NeurAxis to report Q1 2026 financial results and hold update call on May 12

NeurAxis, a medical technology company specializing in neuromodulation therapies, will release its first quarter 2026 financial results on May 12, before the market opens. The company will also host a conference call at 9:00 am ET that day to discuss the results and provide a business update. NeurAxis focuses on its IB-Stim technology, FDA-cleared for treating functional abdominal pain related to IBS and other conditions, with ongoing clinical trials for additional uses. This update is important for investors tracking the company's progress and adoption of its therapies.